Autres langues IRLAB Therapeutics AB

Actions

IRLAB A

SE0012675361

Produits pharmaceutiques

PEA

Temps Différé Nasdaq Stockholm 12:48:47 18/09/2026			Varia. 5j.	Varia. 1 janv.
1,738 ^SEK	+0,23 %		-5,95 %	-11,78 %

03/09	Irlab : la directrice générale Kristina Torfgård quittera ses fonctions en 2027	FW
03/09	La directrice générale d'Irlab, Kristina Torfgård, souhaite quitter ses fonctions	FW

Autres langues

03/09	IRLAB's CEO Intends to Step Down During the First Quarter of 2027
03/09	IRLAB’s CEO intends to step down during the first quarter of 2027
03/09	IRLAB Therapeutics AB Announces Resignation of Kristina Torfgård from CEO Role
31/08	New number of shares and votes in IRLAB Therapeutics AB
26/08	IRLAB Therapeutics AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
26/08	IRLAB publishes interim report for the period January - June 2026
20/08	IRLAB: Invitation to the interim report for Q2 2026 presentation and webcast
19/08	IRLAB's Drug Candidate IRL757 Receives the Generic Name Linepemat from The WHO
19/08	IRLAB’s Drug Candidate IRL757 Receives the Generic Name linepemat from the WHO
19/08	IRLAB Therapeutics AB's Drug Candidate IRL757 Receives Generic Name Linepemat From WHO And Provides Update On Clinical Development
31/07	New number of shares and votes in IRLAB Therapeutics AB
10/07	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares
30/06	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors
30/06	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB
30/06	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln
30/06	Irlab Therapeutics Raises SEK76.5 Million from Oversubscribed Rights Offering
16/06	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies
16/06	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies
16/06	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies
05/06	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026
05/06	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received
05/06	Report from the Extraordinary General Meeting of IRLAB Therapeutics AB
03/06	IRLAB Participates at Aktiedagarna in Stockholm on June 9
03/06	IRLAB participates at Aktiedagarna in Stockholm on June 9.
06/05	IRLAB Therapeutics : Financial Report (irlab q1 2026 eng final)